Albireo Pharma Inc. Common Stock (NASDAQ:ALBO)

Home >> Stock >> Albireo Pharma Inc. Common Stock >> Reports

Albireo Pharma, Inc. is a biopharmaceutical company. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States....

+See More

Blog+More

We share famous inspirational stock market quotes by Warren Buffett, Peter Lynch, Benjamin Graham, and several others.

Laura Hermes

2018-08-31 08:42:00 Friday ET

We share famous inspirational stock market quotes by Warren Buffett, Peter Lynch, Benjamin Graham, and several others.

We share several famous inspirational stock market quotes by Warren Buffett, Peter Lynch, Benjamin Graham, Ben Franklin, Philip Fisher, and Michael Jensen.

+See More

Broadcom announces its strategic plans to move its legal headquarters from Singapore to America.

Daphne Basel

2017-11-03 06:41:00 Friday ET

Broadcom announces its strategic plans to move its legal headquarters from Singapore to America.

Broadcom, a one-time division of Hewlett-Packard and now a semiconductor maker whose chips help power iPhone X, has announced its strategic plans to move it

+See More

The semiconductor microchip demand-supply imbalance remains severe for American big tech.

Amy Hamilton

2022-05-30 09:32:00 Monday ET

The semiconductor microchip demand-supply imbalance remains severe for American big tech.

The new semiconductor microchip demand-supply imbalance remains quite severe for the U.S. tech and auto industries.  Our current fundamental macro a

+See More

Global climate change can cause an adverse impact on long-term real GDP economic growth.

Dan Rochefort

2019-10-27 17:37:00 Sunday ET

Global climate change can cause an adverse impact on long-term real GDP economic growth.

International climate change can cause an adverse impact on long-term real GDP economic growth. USC climate change economist Hashem Pesaran and his co-autho

+See More

Our proprietary alpha investment model outperforms most stock market indexes from 2017 to 2026.

Olivia London

2026-02-02 12:30:00 Monday ET

Our proprietary alpha investment model outperforms most stock market indexes from 2017 to 2026.

With U.S. fintech patent approval, accreditation, and protection for 20 years, our proprietary alpha investment model outperforms most stock market indexes

+See More

Our proprietary alpha investment model outperforms most stock market indices such as S&P 500, Dow Jones, and Nasdaq.

Andy Yeh Alpha

2019-02-01 15:35:00 Friday ET

Our proprietary alpha investment model outperforms most stock market indices such as S&P 500, Dow Jones, and Nasdaq.

Our proprietary alpha investment model outperforms the major stock market benchmarks such as S&P 500, MSCI, Dow Jones, and Nasdaq. We implem

+See More